Browse by People


Up a level
Export as [feed] RSS [feed] RSS 2.0 Short Author List
Number of items: 3.


Clark, Richard E ORCID: 0000-0002-1261-3299, Polydoros, Fotios ORCID: 0000-0001-5181-6817, Apperley, Jane F, Milojkovic, Dragana, Pocock, Christopher, Smith, Graeme, Byrne, Jenny L, de lavallade, Hugues, O'Brien, Stephen G, Coffey, Tony
et al (show 2 more authors) (2017) De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial. LANCET HAEMATOLOGY, 4 (7). E310 - E316.


Clark, Richard E ORCID: 0000-0002-1261-3299, Polydoros, Fotios, Apperley, Jane F, Milojkovic, Dragana, Rothwell, Katherine, Pocock, Christopher, Byrne, Jennifer, de lavallade, Hugues, Osborne, Wendy, Robinson, Lisa
et al (show 4 more authors) (2019) De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. LANCET HAEMATOLOGY, 6 (7). E375 - E383.


Austin, Gemma M, Knight, Katy, Bell, Joanne, Carter, Anthony, Heartin, Earnest, Watson, David, Foroni, Letizia, Christmas, Stephen E, Polydoros, Fotios and Clark, Richard E ORCID: 0000-0002-1261-3299
(2019) The effect on lymphocyte subsets of decreasing/stopping tyrosine kinase inhibitor therapy in chronic myeloid leukaemia: data from the DESTINY trial. BRITISH JOURNAL OF HAEMATOLOGY, 185 (4). 791 - 793.

This list was generated on Tue Nov 19 22:23:39 2019 GMT.